Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

Abstract

The data for this study were provided by the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). The BSRBR-RA is funded by a grant from the BSR. The BSR currently receives funding from AbbVie, Pfizer, Roche and UCB and in the past from Swedish Orphan Biovitrium and Merck. This income finances a wholly separate contract… (More)
DOI: 10.1093/rheumatology/kew040

2 Figures and Tables

Topics

  • Presentations referencing similar topics